Literature DB >> 1304379

Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates.

J Stürzebecher1, U Neumann, U Kohnert, G B Kresse, S Fischer.   

Abstract

BM 06.022 is a t-PA deletion variant that is produced as inactive inclusion bodies in Escherichia coli and transformed into the native form by an in vitro refolding process. Until now, no X-ray and NMR structures of BM 06.022 were available. Therefore a detailed kinetic analysis of the hydrolysis of peptide substrates and of the inhibition by several benzamidine-derived inhibitors was carried out in order to assess that the active site region of the protease domain of BM 06.022 is correctly structured in comparison with t-PA. Our data reveal that the single-chain as well as the two-chain form of BM 06.022 and native t-PA are similar in catalytic and in inhibitor binding properties. This indicates that the active site and the highly complex rearrangement of t-PA upon cleavage of the Arg275-Ile276 bond are maintained in BM 06.022.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1304379      PMCID: PMC2142171          DOI: 10.1002/pro.5560010806

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  14 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

Review 2.  Second-generation plasminogen activators.

Authors:  T J Harris
Journal:  Protein Eng       Date:  1987-12

Review 3.  Serine proteases: structure and mechanism of catalysis.

Authors:  J Kraut
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

4.  Geometry of binding of the benzamidine- and arginine-based inhibitors N alpha-(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-pipe ridine (NAPAP) and (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8- quinolinesulphonyl)-L-arginyl]-2-piperidine carboxylic acid (MQPA) to human alpha-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin.

Authors:  W Bode; D Turk; J Stürzebecher
Journal:  Eur J Biochem       Date:  1990-10-05

5.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

6.  High resolution analysis of functional determinants on human tissue-type plasminogen activator.

Authors:  W F Bennett; N F Paoni; B A Keyt; D Botstein; A J Jones; L Presta; F M Wurm; M J Zoller
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

7.  Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022.

Authors:  U Kohnert; R Rudolph; J H Verheijen; E J Weening-Verhoeff; A Stern; U Opitz; U Martin; H Lill; H Prinz; M Lechner
Journal:  Protein Eng       Date:  1992-01

8.  Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.

Authors:  D Collen; J M Stassen; B J Marafino; S Builder; F De Cock; J Ogez; D Tajiri; D Pennica; W F Bennett; J Salwa
Journal:  J Pharmacol Exp Ther       Date:  1984-10       Impact factor: 4.030

9.  Substrate specificity of tissue-type and urokinase-type plasminogen activators.

Authors:  D C Rijken; E Groeneveld
Journal:  Biochem Biophys Res Commun       Date:  1991-01-31       Impact factor: 3.575

10.  [Synthetic inhibitors of serine proteinases. 13. Quantitative structure-activity relationship for inhibition of trypsin and thrombin by 4-amidinophenyl compounds with a ketone structure].

Authors:  J Stürzebecher; F Markwardt; G Wagner; P Walsmann
Journal:  Acta Biol Med Ger       Date:  1976
View more
  6 in total

1.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

Review 2.  Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.

Authors:  S Noble; D McTavish
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 3.  Thrombolytic agents in development.

Authors:  M Verstraete; H R Lijnen; D Collen
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

4.  Active site labeling with dansyl-glutamyl-glycyl-arginyl chloromethyl ketone demonstrates the full activity of the refolded and purified tissue-type plasminogen activator variant BM 06.022.

Authors:  U Kohnert; M Wozny; M Llinas; A Roos; S Fischer
Journal:  Appl Biochem Biotechnol       Date:  1995-11       Impact factor: 2.926

Review 5.  Fibrinolytic Enzymes for Thrombolytic Therapy.

Authors:  Swaroop S Kumar; Abdulhameed Sabu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

6.  Recombinant Expression of Thrombolytic Agent Reteplase in Marine Microalga Tetraselmis subcordiformis (Chlorodendrales, Chlorophyta).

Authors:  Chunhui Wu; Caiyun Zheng; Jinxia Wang; Peng Jiang
Journal:  Mar Drugs       Date:  2021-05-28       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.